| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439319 | European Journal of Cancer | 2018 | 5 Pages |
Abstract
Our data suggest that anti-PD(L)1 therapy should be resumed if progression occurs after a planned anti-PD(L)1 interruption. Further prospective studies are needed to confirm these results.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
A. Bernard-Tessier, C. Baldini, Patricia Martin, Stéphane Champiat, Antoine Hollebecque, Sophie Postel-Vinay, Andrea Varga, Rastilav Bahleda, Anas Gazzah, Jean-Marie Michot, Vincent Ribrag, Jean-Pierre Armand, Aurélien Marabelle, Jean-Charles Soria,